Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series
Authors' conclusion
ABA demonstrated favourable effects on ILD and was well-tolerated.
Study context
- Population
- Patients with interstitial lung disease (ILD) associated with antisynthetase syndrome fulfilling the Solomon criteria, single centre7 female
- Participants
- 8 patients
- Outcome
- Changes after ABA therapy (mean and median changes)
Methodological detailsretrospective, single-centre
- Retrospective
- Single-centre
Main finding
As reported in the abstract
Change in DLCO percentage (p<0.05)
12.3%
Change in King's Brief Interstitial Lung Disease (KBILD) (p<0.01)
21.4
Change in KL-6 (p<0.01)
174.5U/ml
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Female patients
- Seven of the eight
- Mean age, years (SD 6.0)
- 54.4
- Mean DLCO, % (SD 9.2%)
- 53.8%
- Mean KBILD score (SD 13.8)
- 40.6
- Antibodies against Jo-1, PL-12 and PL-7, patients respectively
- three, three, and two
- Median KL-6, U/ml (IQR 1180.5-2431.5)
- 1612.5
Safety
Adverse events related to ABA · during treatment
- No obvious adverse events related to ABA were observed
Original publication
Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series. Clin Exp Rheumatol. Published 30 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →